摘要
目的:本文报告了SUPERSTAR研究的亚组分析,旨在评价年龄≥65岁的中国糖尿病患者对甘精胰岛素(来得时)SoloStar预填充注射笔的满意度和使用情况。方法:一项为期3个月的多中心、观察性、前瞻性登记研究。由医师决定给予SoloStar治疗。基线时收集患者对既往所用注射笔的评价。使用SoloStar注射笔3个月后,收集和分析患者对SoloStar注射笔的满意度和使用情况。结果:共290例老年患者纳入本分析。90.69%的患者使用SoloStar注射笔后评价为"满意或非常满意"。多数患者对SoloStar注射笔在社会层面的评价为"好或很好",因为其私密性好、减少公开场合使用的尴尬(75.52%)、减少患者使用胰岛素的障碍(72.76%)和增强患者对胰岛素治疗的信心(71.71%)。绝大多数患者打算继续使用SoloStar注射笔(96.19%)。SoloStar注射笔被认为在10个技术层面上要显著优于既往使用的胰岛素注射笔。结论:中国老年糖尿病患者对SoloStarR注射笔感到满意,并认为其在10个技术层面的可用性更好。
Objecives： The introduction of insulin pens has provided a more convenient and accurate method of insulin administration for diabetic individuals. To conduct a sub-analysis of the SUPERSTAR study to assess the satisfaction and usability of the Lantus SoloSTAR insulin pen in Chinese diabetic patients aged ≥ 65 years. Mothods： This was a multicenter, observational, 3 month, prospective registry study conducted in Chinese diabetic patients （≥ 65 years of age）. The Lantus SoloSTAR was prescribed at the physicians＇ discretion. At baseline, patients were asked to evaluate their satisfaction and usability of their previous insulin pen if applicable. After 3 months treatment, patients＇ satisfaction and details on SoloSTAR usage were collected and analysed. Rosults： A total of 290 patients were included. Most patients （90.69%） were ＂very satisfied or satisfied＂ with SoloSTAR. Patients rated SoloSTAR as excellent or good in terms of reducing embarrassment when used in public, reducing patient＇ s reluctance to take injections and increasing confidence in the management of diabetes with insulin （75.52%, 72.76% and 71.71%, respectively）. A majority of patients （96.19%） planned to continue to use SoloSTAR. Compared with previously used insulin pens, SoloSTAR was perceived significantly better across 10 technical aspects. Conclusion： Older Chinese diabetic patients were satisfied with soloSTAR and found its usability favorablein terms of 10 technical aspects.
出处
《药品评价》
CAS
2014年第20期16-21,共6页
Drug Evaluation
